• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

A novel oncolytic virotherapy for paclitaxel resistant ovarian cancer

Research Project

Project/Area Number 17K19597
Research Category

Grant-in-Aid for Challenging Research (Exploratory)

Allocation TypeMulti-year Fund
Research Field Tumor biology and related fields
Research InstitutionTottori University

Principal Investigator

NAKAMURA Takafumi  鳥取大学, 医学(系)研究科(研究院), 准教授 (70432911)

Project Period (FY) 2017-06-30 – 2020-03-31
Project Status Completed (Fiscal Year 2019)
Budget Amount *help
¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
Fiscal Year 2018: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2017: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Keywords癌 / バイオマーカー / ウイルス療法 / バイオテクノロジー / トランスレーショナルリサーチ
Outline of Final Research Achievements

In mice bearing paclitaxel-resistant ovarian cancer cells, oncolytic vaccinia virus (OVV) showed efficient anti-tumor activity. We found long non-coding RNA urothelial carcinoma-associated 1 (UCA1) upregulation in the cancer cells promotes OVV cell-to-cell spread via modulating the Cdc42 signaling. These results suggested that UCA1 regulates the oncolytic effects of OVV and might be considered a promising biomarker to predict oncolytic activity in ovarian cancer.

Academic Significance and Societal Importance of the Research Achievements

UCA1は、卵巣癌をはじめ様々ながんにおける発現亢進と抗がん剤耐性能の獲得への関与が報告されているが、がん治療用ワクシニアウイルスとの関連を示唆する報告は全くなかった。本研究において、UCA1の発現亢進はがん治療用ワクシニアウイルスの抗がん効果を増強すること、及びその分子メカニズムを解明した。これらの研究成果は、UCA1をはじめとするバイオマーカーによって、がん治療用ワクシニアウイルスによる抗がん効果を予測できる他に類のないがんウイルス療法の創出につながる。

Report

(4 results)
  • 2019 Annual Research Report   Final Research Report ( PDF )
  • 2018 Research-status Report
  • 2017 Research-status Report
  • Research Products

    (20 results)

All 2019 2018 2017 Other

All Journal Article (2 results) (of which Peer Reviewed: 2 results,  Open Access: 2 results) Presentation (11 results) (of which Int'l Joint Research: 2 results,  Invited: 6 results) Book (2 results) Remarks (4 results) Patent(Industrial Property Rights) (1 results)

  • [Journal Article] Long noncoding RNA UCA1 enhances sensitivity to oncolytic vaccinia virus by sponging miR-18a/miR-182 and modulating the Cdc42/filopodia axis in colorectal cancer2019

    • Author(s)
      Horita Kosuke、Kurosaki Hajime、Nakatake Motomu、Ito Mai、Kono Hiromichi、Nakamura Takafumi
    • Journal Title

      Biochemical and Biophysical Research Communications

      Volume: 516 Issue: 3 Pages: 831-838

    • DOI

      10.1016/j.bbrc.2019.06.125

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] lncRNA UCA1-Mediated Cdc42 Signaling Promotes Oncolytic Vaccinia Virus Cell-to-Cell Spread in Ovarian Cancer2019

    • Author(s)
      Horita Kosuke、Kurosaki Hajime、Nakatake Motomu、Kuwano Nozomi、Oishi Tetsuro、Itamochi Hiroaki、Sato Sho、Kono Hiromichi、Ito Mai、Hasegawa Kosei、Harada Tasuku、Nakamura Takafumi
    • Journal Title

      Molecular Therapy - Oncolytics

      Volume: 13 Pages: 35-48

    • DOI

      10.1016/j.omto.2019.03.003

    • Related Report
      2019 Annual Research Report 2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] 日本発がん治療用ウイルスの創薬2019

    • Author(s)
      中村貴史
    • Organizer
      金沢大学薬学シンポジウム2019
    • Related Report
      2019 Annual Research Report
    • Invited
  • [Presentation] LncRNA UCA1 is a potential biomarker of response to oncolytic virotherapy as well as chemotherapy2019

    • Author(s)
      Horita K, Kurosaki H, Nakamura T
    • Organizer
      The 12th International Oncolytic Virotherapy Conference
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research
  • [Presentation] LncRNA UCA1 is a potential biomarker of response to oncolytic virotherapy as well as chemotherapy for ovarian cancer2019

    • Author(s)
      Nakamura T
    • Organizer
      第78回日本癌学会
    • Related Report
      2019 Annual Research Report
  • [Presentation] LncRNA UCA1 is a potential biomarker of response to oncolytic vaccinia virotherapy and chemotherapy for ovarian cancer2019

    • Author(s)
      Horita K, Kurosaki H, Nakatake M, kuwano N, Ishii K, Kohno H, Ito M, Itamochi H, Oishi T, Harada T, Nakamura T
    • Organizer
      第25回日本遺伝子治療学会
    • Related Report
      2019 Annual Research Report
  • [Presentation] Next-generation oncolytic vaccinia virus for cancer virotherapy2019

    • Author(s)
      Nakamura T
    • Organizer
      国際遺伝子細胞治療シンポジウムIGCT
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research / Invited
  • [Presentation] Predictive biomarkers for cancer virotherapy with oncolytic vaccinia virus2018

    • Author(s)
      Horita K, Kurosaki H, Nakatake M, Kuwano N, Ishii K, Kohno H, Ito M, Itamochi H, Oishi T, Harada T, Nakamura T
    • Organizer
      第24回日本遺伝子細胞治療学会
    • Related Report
      2018 Research-status Report
  • [Presentation] がんのみを標的破壊するワクシニアウイルスベクターの開発2018

    • Author(s)
      中村 貴史
    • Organizer
      日本薬学会 第138年会
    • Related Report
      2017 Research-status Report
    • Invited
  • [Presentation] Tumor-targeted and armed oncolytic vaccinia virus for systemic cancer virotherapy2017

    • Author(s)
      Nakamura T
    • Organizer
      第23回日本遺伝子細胞治療学会
    • Related Report
      2017 Research-status Report
    • Invited
  • [Presentation] 難治性がんを標的破壊する武装化遺伝子組換えワクシニアウイルスによる全身性がんウイルス療法の開発2017

    • Author(s)
      中村 貴史
    • Organizer
      第76回日本癌学会学術総会
    • Related Report
      2017 Research-status Report
    • Invited
  • [Presentation] 分子生物学的アプローチを駆使してウイルスを知り、そしてがん治療に利用する2017

    • Author(s)
      中村 貴史
    • Organizer
      第40回日本分子生物学会年会
    • Related Report
      2017 Research-status Report
    • Invited
  • [Presentation] IncRNA UCA1 has the potential to be a biomarker of therapeutic response to oncolytic vaccinia virus in paclitaxel resistant ovarian cancer.2017

    • Author(s)
      Horita K, Kurosaki H, Nakatake M, Kuwano N, Ishii K, Itamochi H, Oishi T, Harada T, Nakamura T.
    • Organizer
      第23回日本遺伝子細胞治療学会
    • Related Report
      2017 Research-status Report
  • [Book] 先端治療技術の実用化と開発戦略2017

    • Author(s)
      中村貴史
    • Total Pages
      8
    • Publisher
      技術情報協会
    • Related Report
      2017 Research-status Report
  • [Book] 次世代がん治療 : 発症・転移メカニズムからがん免疫療法・ウイルス療法、診断法まで2017

    • Author(s)
      中村貴史
    • Total Pages
      7
    • Publisher
      エヌ・ティー・エス
    • ISBN
      9784860435035
    • Related Report
      2017 Research-status Report
  • [Remarks] 分子医学分野

    • URL

      https://www.med.tottori-u.ac.jp/introduction/medicine/about/3318/3708/27470.html

    • Related Report
      2019 Annual Research Report
  • [Remarks] 研究内容紹介

    • URL

      http://www.med.tottori-u.ac.jp/integbio/522/1198.html

    • Related Report
      2018 Research-status Report 2017 Research-status Report
  • [Remarks] がんナビ

    • URL

      http://medical.nikkeibp.co.jp/leaf/all/cancernavi/report/201301/528660_3.html

    • Related Report
      2017 Research-status Report
  • [Remarks] ウイルスで新しいがん療法の開発をめざす

    • URL

      http://ganshien.umin.jp/research/main/nakamura/index.html

    • Related Report
      2017 Research-status Report
  • [Patent(Industrial Property Rights)] ワクシニアウイルスの増殖・伝搬を増強する宿主制御因子2017

    • Inventor(s)
      中村 貴史,堀田 享佑,黒崎 創,中武 大夢
    • Industrial Property Rights Holder
      国立大学法人鳥取大学
    • Industrial Property Rights Type
      特許
    • Filing Date
      2017
    • Acquisition Date
      2018
    • Related Report
      2018 Research-status Report

URL: 

Published: 2017-07-21   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi